{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:47:42Z","timestamp":1790711262898,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tissue factor pathway inhibitor (TFPI) is an endogenous inhibitor of the extrinsic pathway that negatively regulates thrombin production during coagulation. Under haemophilic conditions, where the intrinsic coagulation pathway is impaired, inhibition of TFPI may improve clotting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>We investigated the ex vivo effects of a human TFPI neutralizing antibody, marstacimab (previously PF\u201006741086), in coagulation assays including rotational thromboelastometry (ROTEM), thrombin generation assay (TGA) and the dilute prothrombin time (dPT) assay, performed in haemophilic whole blood and plasmas. We compared the effects of marstacimab to the effects of recombinant coagulation factors and investigated the reproducibility of marstacimab in restoring haemostasis by comparing its effect in whole blood collected from the same study participants on differing days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Citrated whole blood and plasmas obtained from haemophilia participants were supplemented ex vivo with vehicle, marstacimab, recombinant FVIII (rFVIII) or recombinant factor IX (rFIX) and analysed in ROTEM, TGA and the dPT assay using low tissue factor concentrations to trigger coagulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Marstacimab induced pro\u2010coagulant responses in ROTEM parameters including reduction in clotting times and increases in angle. Similarly, participant plasmas supplemented with marstacimab exhibited improvements in TGA parameters, including reduced lag times, increased peak thrombin concentrations and reductions in dPT clotting time. Concentrations of marstacimab tested showed activity comparable to addition of rFVIII or rFIX and were reproducible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These studies show the ex vivo potency of marstacimab in restoring haemostasis in whole blood and plasmas from haemophilia participants and comparability to ex vivo reconstitution with recombination coagulation factors.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.13820","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T22:34:41Z","timestamp":1563921281000},"page":"797-806","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-4115","authenticated-orcid":false,"given":"Sunita","family":"Patel\u2010Hett","sequence":"first","affiliation":[{"name":"Rare Disease Research Unit Early Clinical Development, Pfizer Inc Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika J.","family":"Martin","sequence":"additional","affiliation":[{"name":"Coagulation Advancement Laboratory, Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University (VCU) Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem M.","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Coagulation Advancement Laboratory, Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University (VCU) Richmond VA USA"},{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy Cairo University Cairo Egypt"},{"name":"Department of Pathology, Microbiology, and Immunology Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Rakhe","sequence":"additional","affiliation":[{"name":"Rare Disease Research Unit Early Clinical Development, Pfizer Inc Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengling","family":"Sun","sequence":"additional","affiliation":[{"name":"Rare Disease Research Unit Early Clinical Development, Pfizer Inc Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine VCU Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda E.","family":"Nolte","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine VCU Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5067-2943","authenticated-orcid":false,"given":"Janice","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine VCU Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra D.","family":"Pittman","sequence":"additional","affiliation":[{"name":"Rare Disease Research Unit Early Clinical Development, Pfizer Inc Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Rare Disease Research Unit Early Clinical Development, Pfizer Inc Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-8523","authenticated-orcid":false,"given":"Donald F.","family":"Brophy","sequence":"additional","affiliation":[{"name":"Coagulation Advancement Laboratory, Department of Pharmacotherapy &amp; Outcomes Science Virginia Commonwealth University (VCU) Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"issue":"22","key":"e_1_2_8_3_1","first-page":"2194","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg J","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood.V69.1.150.150","article-title":"Characterization of the inhibition of tissue factor in serum","volume":"69","author":"Broze GJ","year":"1987","journal-title":"Blood"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.7.1886"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(87)90422-1"},{"issue":"2","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V71.2.335.335","article-title":"The lipoprotein\u2010associated coagulation inhibitor that inhibits the factor VII\u2010tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action","volume":"71","author":"Broze GJ","year":"1988","journal-title":"Blood"},{"issue":"2","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V69.2.645.645","article-title":"Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation","volume":"69","author":"Rao LV","year":"1987","journal-title":"Blood"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.22.8869"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651613"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.6.2020.2020"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2741\/3926"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246686"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.302655"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14207"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04627.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-10-0670"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12659"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000071636"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(91)90120-L"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1182\/blood.V128.22.2566.2566","article-title":"An antibody to tissue factor pathway inhibitor (PF\u201006741086) in combination with recombinant factor VIIa increases hemostasis in hemophilia plasma without excessive thrombin generation","volume":"128","author":"Rakhe S","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-378935"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.220293"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119858109"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.03.010"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646439"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13679"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-10-0706"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13260"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-050435"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15084"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.13820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.13820","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.13820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T03:26:14Z","timestamp":1694316374000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.13820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/hae.13820"],"URL":"https:\/\/doi.org\/10.1111\/hae.13820","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]},"assertion":[{"value":"2019-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}